ACXP enrolls first patient in PATHFINDER ibezapolstat trial
Acurx Pharmaceuticals (ACXP) says the first patient has been enrolled in its PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.
Acurx Pharmaceuticals (ACXP) says the first patient has been enrolled in its PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.